Velcade Has Been Used to Treat Patients with Myeloma in Part

Question

Velcade has been used to treat patients with myeloma in part because of its inhibition of
A)Ras signaling.
B)Hedgehog signaling.
C)NF-κB signaling.
D)TGF-β signaling.
E)None of the above.

Accepted Answer

Velcade (bortezomib) inhibits the proteasome, leading to inhibition of NF-κB signaling. NF-κB is a transcription factor involved in regulating cell survival and proliferation, and is commonly activated in myeloma cells. By inhibiting NF-κB, Velcade induces apoptosis (cell death) in myeloma cells.